A Single-Arm Phase II Study in Japan to Assess the Efficacy and Safety of Aflibercept Administered Every Two Weeks in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Who Progressed During or Following an Oxaliplatin-Based Regimen

Trial Profile

A Single-Arm Phase II Study in Japan to Assess the Efficacy and Safety of Aflibercept Administered Every Two Weeks in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Who Progressed During or Following an Oxaliplatin-Based Regimen

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Aflibercept (Primary) ; Fluorouracil; Irinotecan; Levofolinic acid
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 21 Jan 2017 Preliminary results assessing association between pharmacodynamic biomarkers and overall survival, presented at the 2017 Gastrointestinal Cancers Symposium
    • 21 Jan 2017 Results presented at the 2017 Gastrointestinal Cancers Symposium.
    • 12 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top